Author

Jan Willem Mulder

Observed names: J W MULDER, J W Mulder, J. Mulder, J. W. Mulder, J. W. R. Mulder, J. Willem Mulder, J.W. MULDER, J.W. Mulder, J.‐W. Mulder, JAN W. MULDER, Jan Mulder, Jan W Mulder, Jan W. Mulder, Jan Willem, Jan W. Mulder, Mulder, Jan Willem

Observed institutions: Utrecht University, Maastricht University Medical Centre, Medisch Spectrum Twente, Slotervaartziekenhuis, Amsterdam UMC Location University of Amsterdam, National Institute for Public Health and the Environment, GGD Amsterdam, University of Amsterdam

ORCID: 0000-0002-9768-3797

Observed ORCID: 0000-0002-9768-3797

OpenAlex ID: A5102945216

Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)

1995 · R. Schuurman, M. Nijhuis, et al. · The Journal of Infectious Diseases · 503

Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive Subjects

1992 · C. A. B. Boucher, E. O'Sullivan, et al. · The Journal of Infectious Diseases · 353

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

1990 · C.A.B. Boucher, J.M.A. Lange, et al. · The Lancet · 179

Drug interaction between St John's wort and nevirapine

2001 · Monique M. R. de Maat, Richard M. W. Hoetelmans, et al. · AIDS · 176

Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy

1998 · David M Burger, Richard MW Hoetelmans, et al. · Antiviral Therapy · 156

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1998 · Monique HE Reijers, Gerrit Jan Weverling, et al. · The Lancet · 154

Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

2003 · Monique M.R. de Maat, G. Corine Ekhart, et al. · Clinical Pharmacokinetics · 148

Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus

2010 · Theodora E.M.S. de Vries–Sluijs, Jurriën G.P. Reijnders, et al. · Gastroenterology · 134

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

2000 · Rolf P. G. van Heeswijk, Agnes I. Veldkamp, et al. · AIDS · 130

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy

1998 · Richard M.W. Hoetelmans, Monique H.E. Reijers, et al. · AIDS · 123

Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry

2008 · R. ter Heine, H. Rosing, et al. · Journal of Chromatography B · 116

Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs

2004 · Bregt S Kappelhoff, Kristel M L Crommentuyn, et al. · Clinical Pharmacokinetics · 113

Soluble Receptors for Tumor Necrosis Factor as Predictors of Progression to AIDS in Asymptomatic Human Immunodeficiency Virus Type 1 Infection

1994 · M. H. Godfried, T. van der Poll, et al. · The Journal of Infectious Diseases · 104

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1999 · Rolf P.G. van Heeswijk, Agnes I. Veldkamp, et al. · AIDS · 102

Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individuals

2002 · Monique M. R. De Maat, Alwin D. R. Huitema, et al. · British Journal of Clinical Pharmacology · 98

PDF

Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection

1992 · R J L KLAASSEN, R GOLDSCHMEDING, et al. · Clinical & Experimental Immunology · 98

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment

1992 · Charles A.B. Boucher, Joep M.A. Lange, et al. · AIDS · 95

Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine Monotherapy

1996 · R. T. Schooley, C. Ramirez-Ronda, et al. · The Journal of Infectious Diseases · 93

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

1997 · R.M.W. Hoetelmans, C.H.W. Koks, et al. · Pharmacy World & Science · 91

PDF

Immunological and virological markers in individuals progressing from seroconversion to AIDS

1991 · Rob A Gruters, Fokke G. Terpstra, et al. · AIDS · 86

Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV

2012 · R. Zoutendijk, H. L. Zaaijer, et al. · The Journal of Infectious Diseases · 79

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection

1998 · Rolf P.G van Heeswijk, Richard M.W Hoetelmans, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 77

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV‐1‐infected patients

2005 · K. M. L. Crommentuyn, B. S. Kappelhoff, et al. · British Journal of Clinical Pharmacology · 73

PDF

Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis

2020 · Astrid M Newsum, Amy Matser, et al. · Clinical Infectious Diseases · 70

High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva

1998 · Richard M.W Hoetelmans, Marjolijn van Essenberg, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 69

Works count: 134

Citation count: 6,029

H-index: 46

I10-index: 95